This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): AGN199201, AGN-199201, Vicept V-101
V-101 is a topical cream for the treatment of the erythema of rosacea. V-101 is a selective G-Protein Modulator primarily through alpha adrenergic receptor activation.
At some point after Allergan's acquisition of Vicept, the Company renamed V-101 into AGN-199201.
V-101 was originally developed by Vicept Therapeutics.
Vicept and Allergan
In July 2011, Vicept and Allergan announced that they entered into a definitive agreement for Allergan to acquire all of the outstanding shares and assets of the privately-held dermatology company. The agreement includes a $75 million cash up-front payment by Allergan plus up to an aggregate of $200 million in payments payable by Allergan contingent upon achieving certain future development and regulatory milestones plus additional payments contingent upon acquired products achieving certain sales milestones. The transaction closed in the same month.
Actavis and Allergan
In November 2014, Actavis and Allergan announced that they have entered into a definitive agreement under which Actavis will acquire Allergan for a combination of $129.22 in cash and 0.3683 Actavis shares for each share of Allergan common stock. Based on the closing price of Actavis shares on November 14,...See full deal structure in Biomedtracker
Additional information available to subscribers only: